価格表

在庫・価格 : 2025年04月26日 15時26分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
VEGF-D, Human, ELISA Kit, Quantikine (96well)
データシート※最新のデータシートでない場合があります
DVED00 RSDアールアンドディー システムズ
R&D Systems, Inc.
1 kit ¥116,000 1個 追加

在庫・価格 : 2025年04月26日 15時26分 現在

VEGF-D, Human, ELISA Kit, Quantikine (96well)

  • 商品コード:DVED00
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥116,000
  • 在庫:1個
使用文献
No. 文献情報 備考 参照
1 George ML et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia ;3(5):420-7
George ML et al
human serum PubMed
2 Fink AM et al. Serum level of VEGF-D in patients with primary lymphedema. Lymphology 2004 Dec;37(4):185-9
Fink AM et al
2004/01/01
Sample Type: Serum PubMed
3 Akahane M et al. A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res. ;25(2A):701-7
Akahane M et al
Sample Type: Cell Supernates PubMed
4 K端mmel S et al. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Res. ;26(2C):1719-26
K端mmel S et al
human plasma (EDTA) PubMed
5 Laakkonen P et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007 Jan;67(2):593-9
Laakkonen P et al
2007/01/01
Sample Type: Cell Supernates PubMed
6 Kholov叩 I et al. Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. Hum. Gene Ther. 2007 Mar;18(3):232-44
Kholov叩 I et al
2007/01/01
Sample Type: Homogenized Tissue,Plasma (Not Specified) PubMed
7 Lee CY et al. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br. J. Cancer 2007 Oct;97(7):877-82
Lee CY et al
2007/01/01
Species: Human, Sample type: Plasma (Not Specified) PubMed
8 Koponen JK et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol. Ther. 2007 Dec;15(12):2172-7
Koponen JK et al
2007/01/01
Species: Human, Sample type: Cell Supernates PubMed
9 Simiantonaki N et al. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int. J. Oncol. 2008 Mar;32(3):585-92
Simiantonaki N et al
2008/01/01
Species: Human, Application: Cell Supernates PubMed
10 Sorrentino A et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp. Hematol. 2008 Aug;36(8):1035-46
Sorrentino A et al
2008/01/01
Species: Human, Application: Cell Supernates PubMed
11 Toivanen PI et al. Novel vascular endothelial growth factor D variants with increased biological activity. J. Biol. Chem. 2009 Jun;284(23):16037-48
Toivanen PI et al
2009/01/01
Sample Type: Cell Supernates PubMed
12 Glasgow CG et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009 May;135(5):1293-300
Glasgow CG et al
2009/01/01
Sample Type: Serum PubMed
13 Papiewska-Pajak I et al. Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC). Exp. Cell Res. 2010 Apr;316(6):907-14
Papiewska-Pajak I et al
2010/01/01
Sample Type: Cell Supernates PubMed
14 Brookes K et al. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br. J. Cancer 2010 May;102(10):1524-32
Brookes K et al
2010/01/01
Sample Type: Plasma (EDTA) PubMed
15 Honda N et al. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis. Br. J. Dermatol. 2010 Oct;163(4):776-80
Honda N et al
2010/01/01
Sample Type: Serum PubMed
16 Konings IR et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer 2010 Sep;103(7):987-92
Konings IR et al
2010/01/01
Sample Type: Serum PubMed
17 Landt S et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011 Aug;31(8):2589-95
Landt S et al
2011/01/01
Sample Type: Serum PubMed
18 Dabora SL et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE 2011;6(9):e23379
Dabora SL et al
2011/01/01
Sample Type: Serum PubMed
19 Majumder M et al. Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE 2012;7(4):e35094
Majumder M et al
2012/01/01
Sample Type: Cell Supernates PubMed
20 Chang WY et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir. Res. 2012;13:34
Chang WY et al
2012/01/01
Sample Type: Serum PubMed
21 Braicu EI et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. ca
Braicu EI et al
2013/01/01
Sample Type: Serum PubMed
22 Gr辿pin R et al. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res. 2014 Feb;74(3):873-83
Gr辿pin R et al
2014/01/01
Sample Type: Tissue Culture Supernates PubMed
23 Weinkopff T et al. Filarial excretory-secretory products induce human monocytes to produce lymphangiogenic mediators. PLoS Negl Trop Dis 2014 Jul;8(7):e2893
Weinkopff T et al
2014/01/01
Sample Type: Cell Culture Supernates PubMed
24 Sallinen H et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696
Sallinen H et al
2014/01/01
Sample Type: Serum PubMed
25 Chou CH et al. Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling. Sci Rep 2016 Jul;6:29029
Chou CH et al
2016/01/01
Sample Type: Cell Culture Supernates PubMed
26 Nascimento ECTD et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir. Res. 2018 05;19(1):83
Nascimento ECTD et al
2018/01/01
Species: Human PubMed
27 Chin TH et al. Application of non-invasive detection of peripheral vascular dysfunction in ovarian hyperstimulation syndrome (OHSS): A pilot study of clinical relevance. Taiwan J Obstet Gynecol 2019 May;58(3):354-358
Chin TH et al
2019/01/01
PubMed
28 Hirose M et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS ONE 2019;14(2):e0212776
Hirose M et al
2019/01/01
PubMed
29 Kumar NP et al. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J. Infect. 2017 01;74(1):10-21
Kumar NP et al
2017/01/01
PubMed
30 Chebib N et al. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration. Sci Rep 2018 Oct;8(1):14698
Chebib N et al
2018/01/01
PubMed
31 Kumar NP et al. Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE 2016;11(1):e0146318
Kumar NP et al
2016/01/01
PubMed
  • No.: 1
  • 文献情報:
    George ML et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia ;3(5):420-7
    George ML et al
  • 備考:
    human serum
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Fink AM et al. Serum level of VEGF-D in patients with primary lymphedema. Lymphology 2004 Dec;37(4):185-9
    Fink AM et al
    2004/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Akahane M et al. A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res. ;25(2A):701-7
    Akahane M et al
  • 備考:
    Sample Type: Cell Supernates
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    K端mmel S et al. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Res. ;26(2C):1719-26
    K端mmel S et al
  • 備考:
    human plasma (EDTA)
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Laakkonen P et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007 Jan;67(2):593-9
    Laakkonen P et al
    2007/01/01
  • 備考:
    Sample Type: Cell Supernates
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kholov叩 I et al. Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. Hum. Gene Ther. 2007 Mar;18(3):232-44
    Kholov叩 I et al
    2007/01/01
  • 備考:
    Sample Type: Homogenized Tissue,Plasma (Not Specified)
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Lee CY et al. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br. J. Cancer 2007 Oct;97(7):877-82
    Lee CY et al
    2007/01/01
  • 備考:
    Species: Human, Sample type: Plasma (Not Specified)
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Koponen JK et al. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol. Ther. 2007 Dec;15(12):2172-7
    Koponen JK et al
    2007/01/01
  • 備考:
    Species: Human, Sample type: Cell Supernates
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Simiantonaki N et al. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int. J. Oncol. 2008 Mar;32(3):585-92
    Simiantonaki N et al
    2008/01/01
  • 備考:
    Species: Human, Application: Cell Supernates
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Sorrentino A et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp. Hematol. 2008 Aug;36(8):1035-46
    Sorrentino A et al
    2008/01/01
  • 備考:
    Species: Human, Application: Cell Supernates
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Toivanen PI et al. Novel vascular endothelial growth factor D variants with increased biological activity. J. Biol. Chem. 2009 Jun;284(23):16037-48
    Toivanen PI et al
    2009/01/01
  • 備考:
    Sample Type: Cell Supernates
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Glasgow CG et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009 May;135(5):1293-300
    Glasgow CG et al
    2009/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Papiewska-Pajak I et al. Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC). Exp. Cell Res. 2010 Apr;316(6):907-14
    Papiewska-Pajak I et al
    2010/01/01
  • 備考:
    Sample Type: Cell Supernates
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Brookes K et al. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br. J. Cancer 2010 May;102(10):1524-32
    Brookes K et al
    2010/01/01
  • 備考:
    Sample Type: Plasma (EDTA)
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Honda N et al. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis. Br. J. Dermatol. 2010 Oct;163(4):776-80
    Honda N et al
    2010/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Konings IR et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer 2010 Sep;103(7):987-92
    Konings IR et al
    2010/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Landt S et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011 Aug;31(8):2589-95
    Landt S et al
    2011/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Dabora SL et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE 2011;6(9):e23379
    Dabora SL et al
    2011/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Majumder M et al. Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE 2012;7(4):e35094
    Majumder M et al
    2012/01/01
  • 備考:
    Sample Type: Cell Supernates
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Chang WY et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir. Res. 2012;13:34
    Chang WY et al
    2012/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Braicu EI et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. ca
    Braicu EI et al
    2013/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Gr辿pin R et al. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res. 2014 Feb;74(3):873-83
    Gr辿pin R et al
    2014/01/01
  • 備考:
    Sample Type: Tissue Culture Supernates
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Weinkopff T et al. Filarial excretory-secretory products induce human monocytes to produce lymphangiogenic mediators. PLoS Negl Trop Dis 2014 Jul;8(7):e2893
    Weinkopff T et al
    2014/01/01
  • 備考:
    Sample Type: Cell Culture Supernates
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Sallinen H et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696
    Sallinen H et al
    2014/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Chou CH et al. Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling. Sci Rep 2016 Jul;6:29029
    Chou CH et al
    2016/01/01
  • 備考:
    Sample Type: Cell Culture Supernates
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Nascimento ECTD et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir. Res. 2018 05;19(1):83
    Nascimento ECTD et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Chin TH et al. Application of non-invasive detection of peripheral vascular dysfunction in ovarian hyperstimulation syndrome (OHSS): A pilot study of clinical relevance. Taiwan J Obstet Gynecol 2019 May;58(3):354-358
    Chin TH et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Hirose M et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS ONE 2019;14(2):e0212776
    Hirose M et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Kumar NP et al. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J. Infect. 2017 01;74(1):10-21
    Kumar NP et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Chebib N et al. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration. Sci Rep 2018 Oct;8(1):14698
    Chebib N et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Kumar NP et al. Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE 2016;11(1):e0146318
    Kumar NP et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed